Got Eggs? Not Anymore. EVERY Has a Better Idea

EVERY Company closes $55M Series D to scale precision-fermented egg proteins now selling at Walmart nationwide

6 Apr 2026

As avian flu strains American egg supplies and pushes prices to record levels, a San Francisco food technology firm has secured $55 million to scale a manufacturing platform that produces functional egg proteins without poultry.

The EVERY Company closed a Series D round led by McWin Capital Partners, with participation from Main Sequence, Bloom8, Minerva Foods, Grosvenor Food and Ag, New Agrarian, and SOSV. The raise brings cumulative funding to roughly $294 million, according to the company.

The capital arrives alongside a significant commercial step. Products incorporating EVERY's fermentation-derived proteins are now sold in Walmart locations across the country, a transition from laboratory-scale development to mass-market retail that the company presented as validation of a platform long regarded with cautious interest by the food industry. The two core ingredients, OvoPro and OvoBoost, replicate the functional behavior of conventional egg proteins in applications ranging from baked goods and pasta to protein beverages and coffee products. Both are shipped as shelf-stable powders with an 18-month shelf life, removing the cold-chain requirements and spoilage risk that complicate conventional egg sourcing for large food manufacturers.

Industrial buyers appear to be responding to operational necessity as much as novelty. With domestic egg availability under sustained pressure, the ability to source a consistent, avian flu-immune protein at competitive cost addresses a procurement problem that conventional supply chains have struggled to resolve. Chief Executive Arturo Elizondo has pointed to food manufacturers seeking supply chain resilience as the company's primary growth driver.

Proceeds from the Series D will fund manufacturing expansion and support a path toward profitability, with the high-volume bakery segment serving as the primary near-term target within what the company describes as a $270 billion domestic egg market. Whether precision fermentation can hold its cost position as it scales, and whether food manufacturers will treat it as a durable procurement shift rather than a hedge against temporary shortages, remains to be seen. The answers will likely shape both investor appetite and the pace of adoption across the broader alternative protein sector.